SARS-CoV-2 seroreversion and all-cause mortality in nursing home residents and staff post-primary course vaccination in Belgium between February and December 2021.
Meyers, Eline; De Rop, Liselore; Deschepper, Ellenet al.
[en] [en] BACKGROUND: During COVID-19 vaccine implementation, information on the persistence of antibody response and impact on mortality in nursing home residents was limited, as they were underrepresented in vaccine clinical trials and real-world data was lacking.
OBJECTIVES: (1) Measure the persistence of the SARS-CoV-2 antibody response and predictors for seroreversion after primary course COVID-19 vaccination in nursing home residents compared to staff and (2) assess all-cause mortality and predictors in nursing home residents after primary COVID-19 vaccination.
METHODS: Seroprevalence and mortality data were collected within a national serosurveillance study in 1640 residents and 1368 staff from 69 nursing homes proportionally spread across Belgium between February and December 2021. To assess the persistence of the antibody response, parametric exponential survival models with interval censoring were fitted, reported with the percentage of seroreverters 120 and 140 days post-primary course vaccination. Furthermore, all-cause mortality rate was calculated and COVID-19 mortality was descriptively reported. Predictors of seroreversion and all-cause mortality were estimated using Cox proportional hazards model.
RESULTS: Nursing home residents were 47 % more likely to serorevert in the 10 months after COVID-19 vaccination than staff. Infection naïvety, older age and high resident care dependency level were found as predictors for seroreversion. The all-cause mortality rate in vaccinated residents over 10 months was 14 % (95 % CI 13-16 %) (n = 229). In 2 % of cases, COVID-19 infection was the reported cause of death. Older age, being male, having severe renal, lung, or cardiac disease, or active cancer, and high care dependency level were identified as predictors for all-cause mortality, irrespective of history of SARS-CoV-2 or breakthrough infection.
CONCLUSION/PRACTICAL IMPLICATION: Future COVID-19 vaccination strategies should prioritize (infection naïve) nursing home residents, as they fail to mount a durable antibody response after primary course vaccination. Nevertheless, COVID-19 mortality remained low, representing only 2 % of the all-cause mortality rate. This study was registered on ClinicalTrials.gov (NCT04738695).
Disciplines :
Immunology & infectious disease
Author, co-author :
Meyers, Eline; Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
De Rop, Liselore; LUHTAR, Leuven Unit for HTA Research, Department of Public Health and Primary Care, KU Leuven, 3000 Leuven, Belgium
Deschepper, Ellen; Biostatistics Unit, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
Duysburgh, Els; Department of Epidemiology and Public Health, Sciensano, 1000 Brussels, Belgium
De Burghgraeve, Tine; LUHTAR, Leuven Unit for HTA Research, Department of Public Health and Primary Care, KU Leuven, 3000 Leuven, Belgium
Van Ngoc, Pauline ; Université de Liège - ULiège > Département des sciences cliniques > Médecine générale
Coen, Anja; Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
De Clercq, Nele; Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
Wallaert, Steven; Biostatistics Unit, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
Buret, Laetitia ; Université de Liège - ULiège > Département des sciences cliniques > Médecine générale
Coenen, Samuel; Department of Family Medicine & Population Health, Faculty of Medicine and Health Sciences, University of Antwerp, 2000 Antwerp, Belgium
De Sutter, An; Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
Scholtes, Béatrice ; Université de Liège - ULiège > Département des sciences cliniques > Médecine générale
Verbakel, Jan Y; LUHTAR, Leuven Unit for HTA Research, Department of Public Health and Primary Care, KU Leuven, 3000 Leuven, Belgium, NIHR Community Healthcare Medtech and IVD cooperative, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX1 2JD Oxford, United Kingdom
Cools, Piet; Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
Heytens, Stefan; Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium. Electronic address: stefan.heytens@ugent.be
SARS-CoV-2 seroreversion and all-cause mortality in nursing home residents and staff post-primary course vaccination in Belgium between February and December 2021.
Vandael, E., Latour, K., Islamaj, E., Panis, L.I., Callies, M., Haarhuis, F., et al. COVID-19 cases, hospitalizations and deaths in Belgian nursing homes: results of a surveillance conducted between April and December 2020. Arch Public Health, 80(1), 2022, 45.
Janssens, H., Heytens, S., Meyers, E., De Schepper, E., De Sutter, A., Devleesschauwer, B., et al. Pre-vaccination SARS-CoV-2 seroprevalence among staff and residents of nursing homes in Flanders (Belgium) in fall 2020. Epidemiol Infect 150 (2022), 1–25.
Sciensano. Belgium COVID-19 Epidemiological Situation 2020. Available from: https://lookerstudio.google.com/embed/reporting/c14a5cfc-cab7-4812-848c-0369173148ab/page/cUWaB Last accessed on 10 February 2025.
Cox, L.S., Bellantuono, I., Lord, J.M., Sapey, E., Mannick, J.B., Partridge, L., et al. Tackling immunosenescence to improve COVID-19 outcomes and vaccine response in older adults. The Lancet Healthy Longevity 1:2 (2020), e55–e57.
Remarque, E.J., de Bruijn, I.A., Boersma, W.J., Masurel, N., Ligthart, G.J., Altered antibody response to influenza H1N1 vaccine in healthy elderly people as determined by HI, ELISA, and neutralization assay. J Med Virol 55:1 (1998), 82–87.
Goodwin, K., Viboud, C., Simonsen, L., Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24:8 (2006), 1159–1169.
Couderc, A.L., Correard, F., Hamidou, Z., Nouguerede, E., Arcani, R., Weiland, J., et al. Factors associated with COVID-19 hospitalizations and deaths in French nursing homes. J Am Med Dir Assoc 22:8 (2021), 1581–7 e3.
Antonelli Incalzi, R., Trevisan, C., Del Signore, S., Volpato, S., Fumagalli, S., Monzani, F., et al. Are vaccines against COVID-19 tailored to the most vulnerable people?. Vaccine 39:17 (2021), 2325–2327.
Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383:27 (2020), 2603–2615.
Meyers, E., De Rop, L., Deschepper, E., Duysburgh, E., De Burghgraeve, T., Van Ngoc, P., et al. Prevalence of SARS-CoV-2 antibodies among Belgian nursing home residents and staff during the primary COVID-19 vaccination campaign. Eur J Gen Pract, 29(2), 2023, 2149732.
Meyers, E., Deschepper, E., Duysburgh, E., De Rop, L., De Burghgraeve, T., Van Ngoc, P., et al. Declining prevalence of SARS-CoV-2 antibodies among vaccinated nursing home residents and staff six months after the primary BNT162b2 vaccination campaign in Belgium: a prospective cohort study. Viruses, 14(11), 2022, 2361.
European Centre for Disease Prevention and Control. Pilot protocol for a COVID-19 vaccine effectiveness study using health data registries. Stockholm: ECDC; 2022. Available from: https://www.ecdc.europa.eu/en/publications-data/covid-19-pilot-protocol-vaccine-effectiveness-study-using-health-data-registries Last accessed on 10 February 2025.
Triest, D., Geebelen, L., De Pauw, R., De Craeye, S., Vodolazkaia, A., Verbrugghe, M., et al. Performance of five rapid serological tests in mild-diseased subjects using finger prick blood for exposure assessment to SARS-CoV-2. J Clin Virol, 142, 2021, 104897.
Sciensano. Specifieke aanbevelingen voor personen met verhoogd risico voor een ernstig verloop van COVID-19 – expert consensus opgesteld onder leiding van prof. Dr Erika Vlieghe. 2021. Available from: https://covid-19.sciensano.be/sites/default/files/Covid19/COVID-19_measures-for-high-risk-groups_NL.pdf Last accessed on 10 February 2025.
Wallace, M.S.M., Katz index of Independence in activities of daily living (ADL). Best practices in nursing care to older adults: The Hartford institute for geriatric nursing. 1998, New York University, College of Nursing.
Caimi, B., Franzetti, M., Velleca, R., Lai, A., Gatti, A., Rossi, P.L., et al. Sero-survey on long-term care facility residents reveals increased risk of sub-optimal antibody response to BNT162b2: implications for breakthrough prevention. BMC Geriatr, 22(1), 2022, 191.
Witkowski, W., Gerlo, S., De Smet, E., Wejda, M., Acar, D., Callens, S., et al. Humoral and cellular responses to COVID-19 vaccination indicate the need for post-vaccination testing in frail population. Vaccines, 10(2), 2022, 260.
Pannus, P., Neven, K.Y., De Craeye, S., Heyndrickx, L., Vande Kerckhove, S., Georges, D., et al. Poor antibody response to BioNTech/Pfizer coronavirus disease 2019 vaccination in severe acute respiratory syndrome coronavirus 2–naive residents of nursing homes. Clin Infect Dis 75:1 (2021), e695–e704.
Van Praet, J.T., Vandecasteele, S., De Roo, A., Vynck, M., De Vriese, A.S., Reynders, M., Dynamics of the cellular and humoral immune response after BNT162b2 messenger ribonucleic acid coronavirus disease 2019 (COVID-19) vaccination in COVID-19-naive nursing home residents. J Infect Dis 224:10 (2021), 1690–1693.
Canaday, D.H., Oyebanji, O.A., Keresztesy, D., Payne, M., Wilk, D., Carias, L., et al. Significant reduction in vaccine-induced antibody levels and neutralization activity among healthcare workers and nursing home residents 6 months following coronavirus disease 2019 BNT162b2 mRNA vaccination. Clin Infect Dis 75:1 (2021), e884–e887.
Tuaillon, E., Pisoni, A., Veyrenche, N., Rafasse, S., Niel, C., Gros, N., et al. Antibody response after first and second BNT162b2 vaccination to predict the need for subsequent injections in nursing home residents. Sci Rep, 12(1), 2022, 13749.
Tut, G., Lancaster, T., Sylla, P., Butler, M.S., Kaur, N., Spalkova, E., et al. Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study. The Lancet Healthy Longevity 3:7 (2022), e461–e469.
Nace, D.A., Kip, K.E., Mellors, J.W., Peck Palmer, O.M., Shurin, M.R., Mulvey, K., et al. Antibody responses after mRNA-based COVID-19 vaccination in residential older adults: implications for reopening. J Am Med Dir Assoc 22:8 (2021), 1593–1598.
Montejano-Hervás, P., Gómez-Pavón, J., Tornero-Torres, O., Valverde-Moyar, M.V., Martín Cruz, B., Vela Carbonera, M., et al. Safety, effectiveness, and immunogenicity 6 months after BNT162B2 mRNA vaccine in frail nursing home residents. Drugs Aging 39:7 (2022), 587–595.
Dyer, A.H., Noonan, C., McElheron, M., Batten, I., Reddy, C., Connolly, E., et al. Previous SARS-CoV-2 infection, age, and frailty are associated with 6-month vaccine-induced anti-spike antibody titer in nursing home residents. J Am Med Dir Assoc 23:3 (2022), 434–439.
Owsianka, I., Pac, A., Jachowicz, E., Gutkowska, K., Szczuciński, W., Maziarz, B., et al. SARS-CoV-2 antibody response after mRNA vaccination in healthcare workers with and without previous COVID-19, a follow-up study from the University Hospital in Krakow, Poland. Front Immunol, 2023, 13.
Igawa, G., Ai, T., Yamamoto, T., Ito, K., Nojiri, S., Saito, K., et al. Antibody response and seroprevalence in healthcare workers after the BNT162b2 vaccination in a University Hospital at Tokyo. Sci Rep, 12(1), 2022, 8707.
Semelka, C.T., DeWitt, M.E., Callahan, K.E., Herrington, D.M., Alexander-Miller, M.A., Yukich, J.O., et al. Frailty and COVID-19 mRNA vaccine antibody response in the COVID-19 community research partnership. The Journals of Gerontology: Series A 77:7 (2022), 1366–1370.
Yao, X., Li, H., Leng, S.X., Inflammation and immune system alterations in frailty. Clin Geriatr Med 27:1 (2011), 79–87.
MacIntyre, C.R., McIntyre, P.B., Ridda, I., Wang, H., Lindley, R.I., Gilbert, G.L., et al. Frailty and immune response to pneumococcal vaccines among the elderly hospitalised patients. Int J Infect Dis, 12, 2008, e142.
Bayram, A., Demirbakan, H., Günel Karadeniz, P., Erdoğan, M., Koçer, I., Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers. J Med Virol 93:9 (2021), 5560–5567.
Fonseca, M.H.G., de Souza, T.F.G., de Carvalho Araújo, F.M., de Andrade, L.O.M., Dynamics of antibody response to CoronaVac vaccine. J Med Virol 94:5 (2022), 2139–2148.
Li, Z., Xiang, T., Liang, B., Deng, H., Wang, H., Feng, X., et al. Characterization of SARS-CoV-2-specific humoral and cellular immune responses induced by inactivated COVID-19 vaccines in a real-world setting. Front Immunol, 12, 2021, 802858.
Violán, C., Carrasco-Ribelles, L.A., Collatuzzo, G., Ditano, G., Abedini, M., Janke, C., et al. Multimorbidity and serological response to SARS-CoV-2 nine months after 1st vaccine dose: European cohort of healthcare workers-orchestra project. Vaccines (Basel), 11(8), 2023.
Huang, C.-F., Jang, T.-Y., Wu, P.-H., Kuo, M.-C., Yeh, M.-L., Wang, C.-W., et al. Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort. Virol J, 20(1), 2023, 112.
Bruel, T., Pinaud, L., Tondeur, L., Planas, D., Staropoli, I., Porrot, F., et al. Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: a community-based, prospective, longitudinal cohort study. eClinicalMedicine, 51, 2022.
Canaday, D.H., Oyebanji, O.A., White, E., Keresztesy, D., Payne, M., Wilk, D., et al. COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents. eBioMedicine, 80, 2022, 104066.
Veronese, N., Koyanagi, A., Stangherlin, V., Mantoan, P., Chiavalin, M., Tudor, F., et al. Mortality attributable to COVID-19 in nursing home residents: a retrospective study. Aging Clin Exp Res 33:6 (2021), 1745–1751.
Nilsson, L., Andersson, C., Kastbom, L., Sjodahl, R., Association between vaccination and preventive routines on COVID-19-related mortality in nursing home facilities: a population-based systematic retrospective chart review. Prim Health Care Res Dev, 23, 2022, e75.
Lafuente-Lafuente, C., Rainone, A., Guerin, O., Drunat, O., Jeandel, C., Hanon, O., et al. COVID-19 outbreaks in nursing homes despite full vaccination with BNT162b2 of a majority of residents. Gerontology 68:12 (2022), 1384–1392.
Greco, G.I., Noale, M., Trevisan, C., Zatti, G., Dalla Pozza, M., Lazzarin, M., et al. Increase in frailty in nursing home survivors of coronavirus disease 2019: comparison with noninfected residents. J Am Med Dir Assoc 22:5 (2021), 943–7 e3.
Booij, J.A., van de Haterd, J., Huttjes, S.N., van Deijck, R., Koopmans, R., Short- and long-term mortality and mortality risk factors among nursing home patients after COVID-19 infection. J Am Med Dir Assoc 23:8 (2022), 1274–1278.
Lu, Y., Jiao, Y., Graham, D.J., Wu, Y., Wang, J., Menis, M., et al. Risk factors for COVID-19 deaths among elderly nursing home Medicare beneficiaries in the Prevaccine period. J Infect Dis 225:4 (2022), 567–577.
Rutten, J.J.S., van Kooten, J., van Loon, A.M., van Buul, L.W., Joling, K.J., Smalbrugge, M., et al. Dementia and Parkinson's disease: risk factors for 30-day mortality in nursing home residents with COVID-19. J Alzheimers Dis 84:3 (2021), 1173–1181.
Panagiotou, O.A., Kosar, C.M., White, E.M., Bantis, L.E., Yang, X., Santostefano, C.M., et al. Risk factors associated with all-cause 30-day mortality in nursing home residents with COVID-19. JAMA Intern Med 181:4 (2021), 439–448.
Reilev, M., Lundby, C., Jensen, J., Larsen, S.P., Hoffmann, H., Pottegard, A., Morbidity and mortality among older people admitted to nursing home. Age Ageing 49:1 (2019), 67–73.
Aw, D., Woodrow, L., Ogliari, G., Harwood, R., Association of frailty with mortality in older inpatients with Covid-19: a cohort study. Age Ageing 49:6 (2020), 915–922.
Pranata, R., Henrina, J., Lim, M.A., Lawrensia, S., Yonas, E., Vania, R., et al. Clinical frailty scale and mortality in COVID-19: a systematic review and dose-response meta-analysis. Arch Gerontol Geriatr, 93, 2021, 104324.
Garcia-Gollarte, J.F., Garcia-Andrade, M.M., Santaeugenia-Gonzalez, S.J., Sola Hermida, J.C., Baixauli-Alacreu, S., Santabalbina, F.J.T., Risk factors for mortality in nursing home residents: an observational study. Geriatrics (Basel), 5(4), 2020.
Domen, J., Verbakel, J.Y.J., Adriaenssens, N., Scholtes, B., Peeters, B., Bruyndonckx, R., et al. Validation of a rapid SARS-CoV-2 antibody test in general practice. BMJ Open, 13(5), 2023, e069997.
Ahmad, A., Fawaz, M.A.M., Aisha, A., A comparative overview of SARS-CoV-2 and its variants of concern. Infez Med 30:3 (2022), 328–343.
